|
|
Long-term treatment plan for previous pt?Long-term treatment plan for previous pt?What is your long-term treatment approach for this patient — What is the duration of induction therapy that you would recommend, and would you modify your approach over time for any reason?
Bahlis NJ et al. Assessing the benefit of continuous treatment in the FIRST trial (MM-020): Impact of response in patients with transplant-ineligible newly diagnosed multiple myeloma. Proc EHA 2015;Abstract P277. Bahlis NJ et al. Impact of response quality on survival outcomes in transplant-ineligible newly diagnosed multiple myeloma (NDMM) patients (pts): Results from the FIRST trial. Proc ASH 2014;Abstract 3458. Benboubker L et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med 2014;371(10):906-17. Abstract Larocca A et al. Reduced dose-intensity subcutaneous bortezomib plus prednisone (VP) or plus cyclophosphamide (VCP) or plus melphalan (VMP) for newly diagnosed multiple myeloma patients older than 75 years of age. Proc ASH 2013;Abstract 539. Mateos MV, San Miguel JF. How should we treat newly diagnosed multiple myeloma patients? Hematology Am Soc Hematol Educ Program 2013;488-95. Abstract |